Chronic Obstructive Pulmonary Disorder market

Chronic Obstructive Pulmonary Disorder (COPD) Market - Global Outlook and Forecast 2022-2028

  • 12 February 2022
  • Life Sciences
  • 64 Pages
  • Report code : PMR-6872838

  • 4.7 (158)

Chronic Obstructive Pulmonary Disorder Market

COMPANIES COVERED

GSK
Pfizer
Merck
Novartis
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Ache
Almirall
Aquinox Pharmaceuticals
Asmacure
Astellas Pharma

Download FREE Report Sample

  Download Free sample

Chronic Obstructive Pulmonary Disorder Market contains market size and forecasts of Chronic Obstructive Pulmonary Disorder (COPD) in Global, including the following market information:

  • Global Chronic Obstructive Pulmonary Disorder (COPD) Market Revenue, 2017-2022, 2023-2028, ($ millions)
  • Global top five companies in 2021 (%)

The global Chronic Obstructive Pulmonary Disorder (COPD) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Short-Acting Bronchodilators Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Chronic Obstructive Pulmonary Disorder (COPD) include GSK, Pfizer, Merck, Novartis, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, Ario Pharma and Roche, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Chronic Obstructive Pulmonary Disorder (COPD) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Chronic Obstructive Pulmonary Disorder (COPD) Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Chronic Obstructive Pulmonary Disorder (COPD) Market Segment Percentages, by Type, 2021 (%)

  • Short-Acting Bronchodilators
  • Corticosteroids
  • Methylxanthines
  • Long-Acting Bronchodilators
  • Phosphodiesterase-4 Inhibitors
  • Others

Global Chronic Obstructive Pulmonary Disorder (COPD) Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Chronic Obstructive Pulmonary Disorder (COPD) Market Segment Percentages, by Application, 2021 (%)

  • Hospital
  • Clinic

Global Chronic Obstructive Pulmonary Disorder (COPD) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Chronic Obstructive Pulmonary Disorder (COPD) Market Segment Percentages, By Region and Country, 2021 (%)

  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Nordic Countries
  • Benelux
  • Rest of Europe
  • Asia
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Rest of Asia
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Middle East & Africa
  • Turkey
  • Israel
  • Saudi Arabia
  • UAE
  • Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

  • Key companies Chronic Obstructive Pulmonary Disorder (COPD) revenues in global market, 2017-2022 (estimated), ($ millions)
  • Key companies Chronic Obstructive Pulmonary Disorder (COPD) revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

  • GSK
  • Pfizer
  • Merck
  • Novartis
  • AstraZeneca
  • Boehringer Ingelheim
  • Teva Pharmaceuticals
  • Ario Pharma
  • Roche
  • Ache
  • Almirall
  • Aquinox Pharmaceuticals
  • Asmacure
  • Astellas Pharma

CHECK TODAYS BEST PRICE

BEST PRICE: $2275
Buy Full Report

Select Licence type with your requirement and needs

SECURITY ASSUREDpayment image

analyst icon
Still not found what you want?

Speak to our Custom Research Team and get the Custom Research in a budget

Custom Research


Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

WHY CHOOSE US

  • Proactive We manage our resources 24/7 to identify issues and address them before they become problems
  • Quality & Reliability We are committed to providing reliable and highly accurate data with an excellent quality control system
  • Global Outreach 6 Major regions and 40+ countries level analysis accomplished
  • Competitive Pricing Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

SOME OF OUR CLIENTS
WHAT SET US APART?
  • quilty

    Quality Assurance

    Focus on Data Accuracy & Reliability
  • quilty

    Trusted by the Best

    75+ Clients in Fortune 500
  • quilty

    Privacy and Security

    All your transactions are secured end-to-end, ensuring a satisfactory purchase
  • quilty

    Competitive Pricing

    Ensure the best and affordable pricing
OUR HAPPY CUSTOMER Some of our customer review
Stay Updated About Chronic Obstructive Pulmonary Disorder Market

Leave This Empty: